Aquestive Therapeutics, Inc. splits its revenue into 6 lines in its filings. The largest line in fiscal 2025, which ended Dec 31, 2025 was Manufacture And Supply Revenue at $40.2 million, 90% of the total.
USD in millions. The percent under a figure is the change from the year before.
| Line |
FY 2026
Sep 30, 2026
|
FY 2025
Dec 31, 2025
|
FY 2024
Dec 31, 2024
|
FY 2023
Dec 31, 2023
|
FY 2022
Dec 31, 2022
|
FY 2021
Dec 31, 2021
|
FY 2020
Dec 31, 2020
|
FY 2019
Dec 31, 2019
|
FY 2018
Dec 31, 2018
|
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
49
|
45
|
58
|
51
|
48
|
51
|
46
|
53
|
67
|
| Manufacture And Supply Revenue |
—
|
40
+0.6%
share 90.3%
|
40
-8.7%
share 69.4%
|
44
+20.4%
share 86.6%
|
36
+3.0%
share 76.3%
|
35
+41.9%
share 69.5%
|
25
share 54.3%
|
—
|
—
|
| Proprietary Product Sales |
—
|
—
|
—
|
—
|
8
-10.0%
share 16.1%
|
9
+50.6%
share 16.7%
|
6
share 12.3%
|
—
|
—
|
| License And Royalty Revenue |
—
|
4
-77.1%
share 7.9%
|
15
+185.4%
share 26.7%
|
5
+128.7%
share 10.6%
|
2
-56.3%
share 4.9%
|
5
-61.7%
share 10.6%
|
14
share 30.7%
|
—
|
—
|
| Co Development And Research Fees |
—
|
1
-33.6%
share 2.9%
|
2
+37.3%
share 3.3%
|
1
+8.4%
share 2.8%
|
1
-20.9%
share 2.7%
|
2
+29.4%
share 3.2%
|
1
share 2.8%
|
—
|
—
|
| Royalty |
—
|
1
-6.9%
share 2.1%
|
1
+201.9%
share 1.8%
|
-1
share -2.0%
|
—
|
-1
share -2.2%
|
—
|
—
|
—
|
| Proprietary Product Revenue |
—
|
-0
-251.7%
share -1.1%
|
0
share 0.5%
|
—
|
—
|
—
|
—
|
—
|
—
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- AQST (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Warren, NJ
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1398733
- Former names
- MonoSol Rx, Inc. (until Mar 27, 2008)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.